Skip to main content

Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division

Written by Customer Service on . Posted in Mergers And Acquisitions.

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION

  • Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader
  • Creation of a global leading provider of kits for genomic typing and transplantation diagnostics
  • Acquisition of a 100% proprietary products portfolio
  • Deeper capabilities and larger scale with technological and commercial complementarities

Paris, July 1st, 2026 ,8 AM CET

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro diagnostics for transplantation, oncology and infectious diseases, today announces that it has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitutes the Lab Products division of CareDx, Inc., a US global precision medicine company focused on transplantation.

Combined with Eurobio Scientific affiliate GenDx’s expertise in next-generation sequencing (“NGS”) assays, software and global commercial footprint, this acquisition brings together two highly complementary portfolios in human leukocyte antigen (“HLA)” typing and transplantation diagnostics.

Strategic Rationale
This acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes.

The integration of CareDx’s Lab Products division strengthens GenDx’s presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories.

Key Highlights

  • Expanded Product Portfolio: Integration of CareDx’s HLA typing kits, including real-time polymerase chain reaction (“PCR”) and NGS-based solutions, with GenDx’s NGS assays and software platforms
  • Global Commercial Scale: Enhanced distribution capabilities and customer access across major transplantation markets
  • Technology Synergies: Acceleration of innovation in high-resolution HLA typing, hybrid capture, and transplantation monitoring workflows
  • Operational Efficiencies: Opportunities to streamline manufacturing and supply chain operations

Transaction details
Eurobio Scientific has acquired CareDx’s Lab Products business for a cash purchase price in the amount of €145 million ($170 million) approximately, after customary adjustments.

Leadership Commentary
“We are happy for the opportunity to close this transaction ahead of schedule and start the journey together with our team and new members towards our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific. “We aim at delivering comprehensive solutions and continued innovation to all our customers and contribute to our patient quality of life.”

John Hanna, CEO of CareDx, added: “We are pleased to complete this transaction and believe the Lab Products portfolio is well positioned under Eurobio Scientific’s ownership and global IVD platform.”

Eurobio Scientific was represented by TD Securities and Kahn Partners.   CareDx was represented by Rothschild & Co. and Fenwick & West LLP.

Next dates
H1 2026 revenues:         July 28, 2026
H1 2026 results:        Oct. 1st 2026

 

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy.

Eurobio Scientific’s reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, “Pépites et Territoires” by AXA & NextStage AM investment program managed by NextStage AM as well as Jérome de Castrie.

For more information, please visit: www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

About GenDx

Genome Diagnostics BV (GenDx) is a leader in the field of high-resolution HLA typing and related molecular diagnostic testing. Established in 2005, it is based in the Utrecht Science Park (USP), the Netherlands, and in San Diego. to support its US customers. The company develops and markets innovative diagnostic tests, software, services and educational products in close collaboration with renowned business partners. With more than 100 employees, the company has a dedicated team of in-house experts always striving to provide the best services for tissue typing laboratories, scientists, and hospital specialists. GenDx’s products are distributed worldwide, either directly or by one of its HLA-specialized distributors. For more information, please visit: https://www.gendx.com

 

  

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.